Navigation Links
LA BioMed investigator, Dr. Yutaka Niihara, developing novel cellular therapy
Date:7/26/2012

LOS ANGELES (July 26, 2012) Yutaka Niihara, M.D., lead investigator at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed), and his team Fawzia Bardag-Gorce, Ph.D. and Joan Oliva Vilana, Ph.D. - are working with Japanese technology company, CellSeed, Inc., to conduct research and examine how novel cellular therapies can help repair damaged organs, including the eyes, skin, teeth, heart, liver, and kidneys. The research is focused on providing innovative solutions for tissue-engineering through the development of novel cell harvest methods and 3-dimensional living tissue replacement products for "cell-sheet therapy" and regenerative medicine. LA BioMed recently completed the first of a two-year research agreement to study CellSeed's proprietary core technology in regenerative medicine.

"At LA BioMed, we are constantly working to uncover new treatments and therapies that can help patients who need them the most," said David I. Meyer, Ph.D., president and CEO of LA BioMed. "We are pleased to be collaborating with CellSeed, and look forward to further exploring the safety and efficacy of this novel cellular therapy and bringing regenerative medicine to patients worldwide."

Cell-sheet therapy is the process of taking small quantities of a patient's own stem or progenitor cells through biopsy and culturing them in a special cell culturing dish. When the cells have grown sufficiently to create a sheet of cells, the living cell-sheet is collected and transplanted back into the patient again. If the transplant is successful, the cells will differentiate to replace the damaged cells and restore the functions that have been lost. This process can be used to regenerate lost or functionally impaired tissues and organs such as eyes, teeth, skin, heart, liver, bladder, and kidneys.

"We are pleased with the progress we have made so far with this potentially revolutionary technology," said Dr. Niihara. "We have already achieved success in Europe to repair corneal tissues that have been damaged by disease, and are working diligently to conduct the studies necessary to meet the requirements that will enable us to bring this technology to America."

To date, this technology has only been tested in Europe and Japan but with rather dramatic results. Patients with blindness due to a lymbal stem cell deficiency have regained their vision, where there had been no previous treatments available to these patients, and there has been a high success rate for patients with end-stage heart failure who have made a full recovery without a heart transplant.

Dr. Niihara and his collaborators have also experienced success in preclinical work including animal studies in their lab. They are hoping to bring this technology to the United States in the very near future, and are working to broaden the range of commercial opportunities for regenerative medicine to include cardiac muscle patches for myocardial infarction, treatment of periodontal disease, cartilage regeneration, and esophageal cancer treatment, among other conditions.

There are several benefits of regenerative medicine. By using a patient's own tissue or cells, there is an on-demand tissue supply and low risk of tissue rejection. There is also no need to wait for a donor, and there are no histology match or foreign tissue rejection risks involved.


'/>"/>
Contact: Diana Soltesz
diana@dsmmedia.com
818-592-6747
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed)
Source:Eurekalert

Related medicine news :

1. LA BioMed offers unique educational and research opportunity to local high school seniors
2. Louisiana Tech biomedical engineering professor earns recognition, funding for research
3. LA BioMed investigator Dr. Christina Wang spearheads study on new male contraceptive gel
4. LA BioMed investigators, Drs. Kevin Bruhn and Noah Craft, develop novel treatment for melanoma
5. UMMS researcher Victor Ambros, Ph.D., named co-recipient of 2012 Janssen Award for Biomedical Research
6. UCSC physicist Alexander Sher named Pew Scholar in the Biomedical Sciences
7. Applied nanobiomedicine: Exploiting nanoparticles to hunt for hidden cancer cells
8. LA BioMeds Dr. Patricia Dickson researching treatments for neurodegenerative disorders
9. LA BioMed receives Grand Challenges Explorations grant
10. Biomedical researchers receive Hartwell Foundation awards
11. LA BioMeds Dr. John Tsuang examines effects of Ibudilast and metamphetamines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... Oklahoma (PRWEB) , ... June 25, 2016 , ... ... both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures ... Oklahoma City area —Johnson is one of the first doctors to perform the ...
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort ... holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain ... Disease (SCD) is a disorder of the red blood cells, which can cause episodes ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... Comfort ... the American Cancer Society and the Road To Recovery® program to drive cancer patients ... seniors and other adults to ensure the highest quality of life and ongoing independence. ...
(Date:6/24/2016)... Nevada (PRWEB) , ... June 24, 2016 , ... ... Vegas client, The Grove Investment Group (TGIG), has initiated cultivation and processing operations ... in Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of a ...
(Date:6/24/2016)... ... June 24, 2016 , ... Advanced Plastic Surgery Institute ( ... as its official Medspa Sponsor. Dr. Josh Olson, a board-certified plastic surgeon, owns ... Dr. Olson says the decision to support the pageant in an official capacity ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... BRAHMS PCT (procalcitonin) assay as a dedicated testing solution ... this clearance, Roche is the first IVD company in ... sepsis risk assessment and management. PCT is ... levels in blood can aid clinicians in assessing the ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
(Date:6/23/2016)... , June 23, 2016 Bracket , a ... its next generation clinical outcomes platform, Bracket eCOA (SM) ... on June 26 – 30, 2016 in Philadelphia ... electronic Clinical Outcome Assessment product of its kind to fully ... Bracket eCOA 6.0 is a flexible platform for ...
Breaking Medicine Technology: